Synthio Labs raises $5M in seed funding round led by Elevation Capital

AI healthcare startup Synthio Labs has raised $5 million in a seed funding round led by Elevation Capital. The round also saw participation from 1984 Ventures, Peak XV Partners, Y Combinator, and several healthcare and AI industry angels.

Synthio Labs is a healthcare-focused voice AI startup enables pharmaceutical companies to automate doctor and patient engagement.

According to Synthio Labs, globally pharma companies spend more than $30 billion a year on doctor and patient engagement, yet outreach remains largely manual, fragmented, and hard to scale. Doctors face information overload, while patients, especially those with chronic conditions, often lack consistent support, leading to treatment drop-off rates as high as 50%, it said in a statement.

The startup aims to address these gaps with compliant, real-time voice AI that can deliver accurate medical information on demand.

CEO and Co-founder Supreet Deshpande said the future of healthcare will depend not only on breakthrough medicines but also on “how we reach and support every clinician and patient who relies on them.” CTO and Co-founder Rajashekar Vasantha said that Synthio is building the AI infrastructure to enable this support “intelligently, compliantly, and at scale.”

The startup’s AI operating system integrates three products:

• Jarvis, a clinical-grade voice AI copilot for pharma field teams
• Ather, a multimodal AI engine for omnichannel engagement
• Simulation Studio, a digital-twin platform that models clinician and patient behaviour for research and strategy

Together, these tools help automate compliant conversations, capture structured insights, and standardise communication across large life-sciences organisations.

Early adopters of these solutions include many top 10 global pharma companies and leading D2C healthcare brands. In one deployment,

According to Synthio, its voice AI has delivered personalised support to more than 5,000 eczema patients in 48 hours, demonstrating its ability to rapidly scale engagement.

Founded by Supreet Deshpande, Sahitya Sridhar, and Rajashekar Vasantha, Synthio Labs has deep India roots, with the founding team having had academic and professional experience in Karnataka and Chennai.

The founders have also held roles across McKinsey, ZS Associates, Amazon, and Audible, contributing to large-scale pharma commercial programmes and foundational LLM and voice-tech development.

Synthio Labs, which has teams in India and the United States, plans to use the capital to expand its engineering and product capabilities, scale deployments across the US and Europe, and deepen partnerships with global life sciences firms. The company aims to make AI-driven engagement the new global standard for clinician and patient support.

Krishna Mehra, AI Partner at Elevation Capital, said Synthio is building the “next major customer engagement infrastructure for life sciences" while noting that pharma’s trillion-dollar commercial machinery is “ripe for reinvention.”

While voice-based automation in healthcare is a growing category, Synthio Labs operates in a relatively specialised niche: clinical-grade voice AI designed specifically for life sciences engagement. While a handful of companies are building voice assistants for healthcare, most startups focus on hospital operations, patient triage, or appointment workflows rather than pharma-doctor communication.

Players such as Tovie AI, Gnani.ai, Botphonic, and Convozen AI offer voicebots for hospitals and clinics, helping automate tasks such as appointment scheduling, symptom checking, and administrative assistance. Others like ElevenLabs and DeepforgeAI provide voice agents for patient access and call-centre automation. These platforms are designed to streamline routine support, often with multilingual capabilities and secure, on-premise deployments.

However, few companies target the life sciences commercial stack as directly as Synthio Labs, which focuses on compliant medical conversations, field-team copilots, and digital twins of clinicians and patients. The company positions itself as not just as another conversational AI tool, but as an AI infrastructure layer for pharma engagement, aiming to unify how drug-makers communicate with doctors and patients globally.